Objective-To study further the Klebsiella specific serum antibody response in patients with axial and peripheral types of ankylosing spondylitis (AS). Methods-IgAl and IgA2 subclass antibodies to Kiebsiella pneumoniae were measured by enzyme linked immunosorbent assay in the sera of 171 patients with axial or peripheral type AS, and in sera of 100 healthy controls. The effect of 26 weeks of sulphasalazine treatment on the antibody levels in the two types of AS was also analysed.
bodies to Kiebsiella pneumoniae were measured by enzyme linked immunosorbent assay in the sera of 171 patients with axial or peripheral type AS, and in sera of 100 healthy controls. The effect of 26 weeks of sulphasalazine treatment on the antibody levels in the two types of AS was also analysed. Results-K pneumoniae specific antibody levels of both IgAl and IgA2 subclasses were increased in the sera of patients with AS compared with healthy controls. The increased levels were present in patients with axial and with peripheral AS, and there were no statistically significant differences in the antibody levels between these two groups. Sulphasalazine treatment decreased the Klebsiella specific antibody level of IgAl subclass in patients with axial AS, but there were no statistically significant changes in the IgA2 subclass, or in the patients with peripheral type AS. Conclusions-These results agree with earlier published findings suggesting that IgA (especially Klebsiella specific IgA) may have a role in the pathogenetic mechanisms of both peripheral and axial types ofAS. In addition, it seems that both IgAl and IgA2 subclasses are involved in the disease process.
(Ann Rheum Dis 1995; 54: 631-635)
The aetiology of ankylosing spondylitis (AS) remains unknown.' The genetic factor HIA B27 evidently has an important role in the pathogenesis,' 2 and a role for gut and mucosal immune defence mechanisms has also been suggested3-gut permeability has been shown to be increased in patients with AS, for example. No statistically significant correlations were seen in patients with axial or with peripheral AS, between the decrease in IgAl and IgA2 subclass Klebsiella antibody levels and the severity of spinal pain, the severity of morning stiffness, ESR, or CRP (these variables were earlier shown to characterise best the activity of AS25). However, in patients with axial AS that were included into the present study, the severity of spinal pain (assessed by visual analogue scale), the severity of morning stiffness (assessed by visual analogue scale), ESR, and CRP seemed to decrease more during the sulphasalazine treatment than they did in patients with peripheral AS (mean changes, respectively: -15, -22, -14 and -20 in axial group, and -11, -8, -7 and -14 in peripheral group).
Discussion
In the present study we have shown that K pneumoniae specific antibody levels of both IgAl and IgA2 subclasses were increased in the sera of patients with AS compared with healthy controls. In addition, the increased IgAl and IgA2 Klebsiella specific antibody levels were seen both in patients with axial and in patients with peripheral type AS, but there were no statistically significant differences in the antibody levels between these two types of AS. This corroborates findings of our recent study in which an increased IgA class Klebsiella specific antibody level was found in both types of AS in these same patients.'6 Thus these findings support earlier published results emphasising the importance of IgA class antibodies, and especially of those with specificity to Kpneumoniae, in the pathogenesis of AS.3 6 11-16 The presence of increased Klebsiella specific IgA subclass antibody levels in the sera of patients with AS may be related to infection, inflammation, or change in the mucosal permeability in the gut. The increased IgAl Klebsiella specific antibody level in patients with AS suggests a non-secretory origin for the increased total serum IgA, which must be ascribed to the central immune system. 17 18 20-22 However, the Klebsiella antibody level of IgA2 subclass was also increased, suggesting a contribution by the mucosa (for example gut) to the increased IgA production.'7 18 20-22 The latter observation is of special interest, as the relation of the gut to inflammatory joint manifestations has received much attention recently. In patients with AS, both ileal and colonic mucosa often show macroscopic and microscopic signs of inflammation, which may resemble an early form of Crohn's disease. It cannot be excluded that use of nonsteroidal anti-inflammatory drugs (NSAID) in the present patients may have had an influence on antibody levels because of their tendency to increase gut permeability,33 as the majority of our patients were taking NSAIDs. Further, during amelioration of the symptoms of AS, the patients reduced their use of NSAIDs, which could have led to a change in mucosal permeability towards normal. This might also have diminished the leakage of bacterial antigens from the gut and led to a decrease in the antibody levels. However, no significant differences were recently seen in the frequency of endoscopically visualised lesions between patients with and without prior NSAID use.27
Furthermore, this does not explain the fact that only in the patients with the axial type of AS did the Klebsiella IgAl subclass antibody levels decrease statistically significantly, as there were no differences in the use of NSAIDs between the two patient groups.
In conclusion, our present results are in agreement with the earlier findings which suggested that IgA (especially Klebsiella specific IgA) may play a role in the pathogenetic mechanisms of both peripheral and axial types of AS. In addition, it seems that both IgAl and IgA2 subclasses are involved in the disease process.
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